BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23340450)

  • 1. Reply: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    Liu P; Brown S; Channathodiyil P; Kannappan V; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2013 Mar; 108(4):994. PubMed ID: 23340450
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'.
    Cvek B
    Br J Cancer; 2013 Mar; 108(4):993. PubMed ID: 23340448
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    Liu P; Brown S; Goktug T; Channathodiyil P; Kannappan V; Hugnot JP; Guichet PO; Bian X; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2012 Oct; 107(9):1488-97. PubMed ID: 23033007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
    Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.
    Serra R; Zhao T; Huq S; Gorelick NL; Casaos J; Cecia A; Mangraviti A; Eberhart C; Bai R; Olivi A; Brem H; Jackson EM; Tyler B
    PLoS One; 2021; 16(11):e0251957. PubMed ID: 34731160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfiram/copper targets stem cell-like ALDH
    Jin N; Zhu X; Cheng F; Zhang L
    J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfiram/Copper Suppresses Cancer Stem Cell Activity in Differentiated Thyroid Cancer Cells by Inhibiting BMI1 Expression.
    Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
    Kast RE; Belda-Iniesta C
    Curr Stem Cell Res Ther; 2009 Dec; 4(4):314-7. PubMed ID: 19500061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
    Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
    Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
    Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells.
    Cao HZ; Yang WT; Zheng PS
    BMC Cancer; 2022 May; 22(1):521. PubMed ID: 35534815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
    Hothi P; Martins TJ; Chen L; Deleyrolle L; Yoon JG; Reynolds B; Foltz G
    Oncotarget; 2012 Oct; 3(10):1124-36. PubMed ID: 23165409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
    Mettang M; Meyer-Pannwitt V; Karpel-Massler G; Zhou S; Carragher NO; Föhr KJ; Baumann B; Nonnenmacher L; Enzenmüller S; Dahlhaus M; Siegelin MD; Stroh S; Mertens D; Fischer-Posovszky P; Schneider EM; Halatsch ME; Debatin KM; Westhoff MA
    Sci Rep; 2018 Apr; 8(1):5527. PubMed ID: 29615749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.
    Wang K; Michelakos T; Wang B; Shang Z; DeLeo AB; Duan Z; Hornicek FJ; Schwab JH; Wang X
    Cancer Lett; 2021 May; 505():37-48. PubMed ID: 33582212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
    Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
    Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.
    Yip NC; Fombon IS; Liu P; Brown S; Kannappan V; Armesilla AL; Xu B; Cassidy J; Darling JL; Wang W
    Br J Cancer; 2011 May; 104(10):1564-74. PubMed ID: 21487404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of disulfiram and H
    Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
    Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
    Raha D; Wilson TR; Peng J; Peterson D; Yue P; Evangelista M; Wilson C; Merchant M; Settleman J
    Cancer Res; 2014 Jul; 74(13):3579-90. PubMed ID: 24812274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.